Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatic lipogenic enzymes are a group of enzymes responsible for catalyzing the synthesis of fatty acids and triglycerides in the liver. The most prominent members include acetyl-CoA carboxylase (ACC), which converts acetyl-CoA to malonyl-CoA; fatty acid synthase (FASN), which elongates carbon chains to form fatty acids; and stearoyl-CoA desaturase 1 (SCD1), which introduces double bonds into fatty acid chains. These enzymes are tightly regulated by transcription factors such as SREBP-1c and ChREBP, and their activities respond to hormonal signals like insulin and nutritional states. Dysregulation of hepatic lipogenesis contributes to the development of metabolic diseases including fatty liver, obesity, and type 2 diabetes. Therapeutically, these enzymes are investigated as drug targets to suppress excessive hepatic lipid production and ameliorate metabolic syndromes.
Inhibition leads to reduced hepatic fatty acid and triglyceride synthesis, improved metabolic profiles, and mitigation of hepatic steatosis and obesity
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic lipogenic enzyme.